But there is no clear path for the new therapies one-time treatments so effective in clinical trials that they have been hailed as cures to reach the countries where the vast majority of people with sickle cell live.
Shortly after the approval their manufacturers announced sticker prices in the millions of dollars: $3.1 million for Lyfgenia, made by Bluebird Bio, and $2.2 million for Casgevy, made by Vertex Pharmaceuticals.
[
add
]
[
|
|
...
]